Aegis Life launched to fight COVID-19 via DNA vaccines and therapeutics enabled by Fusogenix delivery technology
On Sept. 1, 2020, Entos Pharmaceuticals announce the launch of its San Diego-based spinout company Aegis Life, dedicated…
-
-
Titers of antibodies against SARS-CoV2 did not decline within four months
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
-
Lenzilumab COVID-19 case-control study published in Mayo Clinic Proceedings Journal
On Sept. 1, 2020, Humanigen announced the first case-control data of lenzilumab in severe COVID-19 demonstrated an 80%…
-
Disease | NIH | Therapeutics
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
-
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration EUA for Treatment of Patients With Moderate COVID-1
On Aug. 28, 2020, Gilead Sciences announced the U.S. Food and Drug Administration (FDA) expanded the Emergency Use…
-
iBio and Planet Biotechnology entered into exclusive worldwide license agreement for development of a COVID-19 therapeutic
On Aug. 28, 2020, iBio announced that it had entered into an exclusive worldwide license agreement with Planet…
-
RedHill Biopharma Announced Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in…
-
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics | WHO
Laurent Pharmaceuticals received FDA approval to initiate its COVID-19 phase 2 clinical trial in the U.S.
On Aug. 27, 2020, Laurent Pharmaceuticals announced that it had received approval from the U.S. Food and Drug…
-
AIM ImmunoTech decreased SARS-CoV-2 infectious viral yields by 90% using new in vitro model
On Aug. 27, 2020, AIM ImmunoTech announced that it had identified an effective in vitro model at The…
-
Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection
On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…
-
Abbott’s fast, $5, 15-minute, easy-to-use COVID-19 antigen test for healthcare professionals received FDA Emergency Use Authorization
On Aug. 26, 2020, Abbott announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use…
-
Journal of American College of Cardiology published pioneering study using Stereotaxis robotic technology to treat pulmonary hypertension
On Aug. 26, 2020, Stereotaxis announced a pioneering publication in the prestigious Journal of the American College of…
-
Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
On Aug. 25, 2020, AstraZeneca announced that the first participants have been dosed in a Phase I trial…
-
How SARS-CoV-2 spread across greater Boston during pandemic’s first wave
On Aug. 25, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, the Massachusetts…
-
CytoDyn reached enrollment of 195 patients in its phase 3 trial for COVID-19 patients with severe-to-critical symptoms
On Aug. 25, 2020, CytoDyn announced the Company had reached the requisite number of enrolled patients in its…
-
Biotechnology | COVID-19 | FDA | Therapeutics
XBiotech announced COVID-19 candidate therapy
On Aug. 24, 2020, XBiotech announced that the U.S. Food and Drug Administration (FDA) issued an emergency use…
-
Largest global study on hydroxychloroquine safety finds increased cardiovascular risk with azithromycin
On Aug. 24, 2020, the combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including…
-
University of Oxford study described which cancer patients are more vulnerable to COVID-19
On Aug. 24, 2020, a published study led by the Universities of Oxford and Birmingham found that, compared…
-
COVID-19 drug candidate Brilacidin achieved a selectivity index among the highest reported
On Aug. 24, 2020, Innovation Pharma reported receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) based…
-
Quest Diagnostics Foundation launched initiative to reduce health disparities in underserved communities
On Aug. 24, 2020, the Quest Diagnostics Foundation announced a wide-ranging initiative to address and reduce health disparities…
-
Trevena announced initiation of TRV027 study in COVID-19 patients in collaboration with Imperial College London
On Aug. 24, 2020,Trevena announced that Imperial College London (ICL) had initiated a proof-of-concept study for TRV027 in…
-
Mayo Clinic discontinued enrollment in Expanded Access Program for convalescent plasma with FDA Emergency Use Authorization
On Aug. 23, 2020, the Mayo Clinic announced that with the FDA Emergency Use Authorization of convalescent plasma,…
-
JAMA reported on effect of remdesivir vs standard care on clinical status in patients with moderate COVID-19
On Aug. 21, 2020, JAMA reported that hospitalized patients with moderate COVID-19 randomized to a 5-day course of…
-
Sorrento announced agreement to acquire SmartPharm and develop gene-encoded therapeutic antibodies for COVID-19 and cancer therapeutics
On Aug. 20, 2020, Sorrento Therapeutics and SmartPharm Therapeutics announced the signing of a merger agreement under which…
-
GT Biopharma updated development of TriKE(TM) therapeutic for treatment of COVID-19 infection
On Aug. 20, 2020, GT Biopharma and Cytovance announced a collaboration agreement whereby Cytovance will providing drug development…
-
La Jolla Institute for Immunology awarded $6.4 million for international efforts to beat COVID-19
On Aug. 20, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
-
Regeneron and Roche collaborate to significantly increase global supply of REGN-COV2 investigational antibody cocktail for COVID-19
On Aug. 19, 2020, Regeneron and Roche announced that they were joining forces in the fight against COVID-19…
-
CDC data showed disproportionate COVID-19 impact in American Indian/Alaska Native populations
On Aug. 19, 2020, the U.S. Centers for Disease Control and Prevention (CDC) released a new study that…
-
BioNexus KC awarded grant to improve COVID-19 outcomes for patients with underlying health conditions
On Aug. 19, 2018, BioNexus KC announced it had been awarded a $42,900 grant from the Health Forward…
-
Johnson & Johnson acquired Momenta Pharmaceuticals for $6.5 billion
On Aug. 19, 2020, Johnson & Johnson announced an agreement to acquire Momenta Pharmaceuticals, a company that discovers…
